An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Gynecologic Oncology

• Publication date

  2018-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2018.01.006PMID 29422345PMCID PMC5896309
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Statin use and the risk of ovarian and endometrial cancers: a meta-analysis

  2019cited by this paper
• Statin therapy and association with ovarian cancer risk in the New England Case Control (NEC) study

  2018cited by this paper
• Prospective analysis of association between statins and pancreatic cancer risk in the Women’s Health Initiative

  2016cited by this paper
• DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology

  2015cited by this paper
• Prospective Analysis of Association between Statin Use and Breast Cancer Risk in the Women's Health Initiative

  2013cited by this paper
• The effect of statins on risk and survival of gynecological malignancies.

  2013cited by this paper
• Prospective analysis of association between use of statins and melanoma risk in the Women's Health Initiative

  2012cited by this paper
• Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk.

  2012cited by this paper
• Molecular targets of phytochemicals for cancer prevention

  2011cited by this paper
• Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression

  2011cited by this paper
• Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells.

  2010cited by this paper
• Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort.

  2010cited by this paper
• Incidence of cancer and statin usage—Record linkage study

  2010cited by this paper
• Statin use and cancer risk: a comprehensive review

  2010cited by this paper
• Statin use and female reproductive organ cancer risk in a large population-based setting

  2009cited by this paper
• Trends in Statin Use and Low-Density Lipoprotein Cholesterol Levels Among US Adults: Impact of the 2001 National Cholesterol Education Program Guidelines

  2008cited by this paper
• Statins and cancer risk.

  2008cited by this paper
• Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis‐associated colon cancer in mice

  2008cited by this paper
• Statin use and risk of breast cancer

  2008cited by this paper
• Screening statins for possible carcinogenic risk: up to 9 years of follow‐up of 361 859 recipients

  2008cited by this paper
• Statin Use and the Risk of 10 Cancers

  2007cited by this paper
• Trial watch

  2007cited by this paper
• Statin use and breast cancer: prospective results from the Women's Health Initiative.

  2006cited by this paper
• Statins and the risk of cancer.

  2006cited by this paper
• Statins and the risk of cancer.

  2006cited by this paper
• A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes.

  2006cited by this paper
• Cancer risk among statin users: A population‐based cohort study

  2005cited by this paper
• Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update

  2005cited by this paper
• Statin use and cancer risk in the General Practice Research Database

  2004cited by this paper
• The risk of cancer in users of statins.

  2004cited by this paper
• The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures.

  2003cited by this paper
• Implementation of the Women's Health Initiative study design.

  2003cited by this paper
• Statin use and the risk of breast cancer.

  2003cited by this paper
• Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells.

  2002cited by this paper
• Isoprenoids influence expression of Ras and Ras-related proteins.

  2002cited by this paper
• Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

  2002cited by this paper
• Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells

  2001cited by this paper
• Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors.

  2001cited by this paper
• HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2.

  2001cited by this paper
• Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study.

  2001cited by this paper
• 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study.

  2000cited by this paper
• Measurement characteristics of the Women's Health Initiative food frequency questionnaire.

  1999cited by this paper
• Rho as a mediator of G protein-coupled receptor signaling.

  1999cited by this paper
• Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group.

  1998cited by this paper
• Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors.

  1998cited by this paper
• Inhibition of the 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Pathway Induces p53-independent Transcriptional Regulation of p21 WAF1/CIP1 in Human Prostate Carcinoma Cells*

  1998cited by this paper
• Cancer principles and practice of oncology

  1997cited by this paper

• Use of statins and risk of ovarian cancer: evidence on effect modification by parity, menopause and endometriosis from nationwide nested case-control studies.

  2025cites this paper
• Statins and the risk of gynecological cancer: a Norwegian population-based cohort study

  2025cites this paper
• Statins in the Cause and Prevention of Cancer: Confounding by Indication and Mediation by Rhabdomyolysis and Phosphate Toxicity

  2024influential citation
• Statin therapy and upper tract urothelial carcinoma risk in hyperlipidemic patients with chronic kidney disease and end-stage kidney disease, a population-based 17-year follow-up study

  2024cites this paper
• Causal relationship between lipid-lowering drugs and ovarian cancer, cervical cancer: a drug target mendelian randomization study

  2024cites this paper
• Drug Repositioning for Ovarian Cancer Treatment: An Update.

  2024cites this paper
• Use of statins and risks of ovarian, uterine, and cervical diseases: a cohort study in the UK Biobank

  2024cites this paper
• Statin use and ovarian cancer outcomes

  2024cites this paper
• The possible role furin and furin inhibitors in endometrial adenocarcinoma: A narrative review

  2023cites this paper
• Advances in ovarian cancer treatment using a combination of statins with other drugs

  2023cites this paper
• Statins as Repurposed Drugs in Gynecological Cancer: A Review

  2022cites this paper
• Possibilities of using statins in comprehensive antitumor treatment

  2022cites this paper
• Targeting nutrient metabolism with FDA-approved drugs for cancer chemoprevention: Drugs and mechanisms.

  2021cites this paper
• Statins as adjuvants in the treatment of ovarian cancer: controversy and misunderstanding.

  2021cites this paper
• Statins in mature B‐cell lymphomas and leukaemias

  2021cites this paper
• Association between statin use and the risk, prognosis of gynecologic cancer: A meta-analysis.

  2021cites this paper
• Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer

  2021cites this paper
• Statin and cyclooxygenase‐2 inhibitors improve survival in newly diagnosed diffuse large B‐cell lymphoma: a large population‐based study of 4913 subjects

  2020cites this paper
• LDL, HDL and endocrine-related cancer: from pathogenic mechanisms to therapies.

  2020cites this paper
• Do statins play any role in reducing the incidence and mortality of ovarian cancer? A systematic review and meta-analysis

  2020influential citation
• Association between statin use and second cancer risk in breast cancer patients: a nationwide population-based cohort study

  2020cites this paper
• Statins in risk-reduction and treatment of cancer

  2020cites this paper
• Systematic review and meta-analysis of studies assessing the relationship between statin use and risk of ovarian cancer

  2020cites this paper
• Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System

  2020cites this paper
• Statin use and the risk of ovarian and endometrial cancers: a meta-analysis

  2019cites this paper
• Metformin, statins and the risk and prognosis of endometrial cancer in women with type 2 diabetes

  2019cites this paper
• Statin therapy: does sex matter?

  2019cites this paper
• ’ s response to reviews Title : Statin use and the risk of ovarian and endometrial cancers : A meta-analysis

  2019cites this paper
• Calidad de vida en el climaterio: acercamiento al estudio de la salud integral y la conformidad con normas de género femeninas

  2018cites this paper
• Statin therapy and association with ovarian cancer risk in the New England Case Control (NEC) study

  2018cites this paper
• Reviews covering publications from February 15, 2018 – August 15, 2018

  2018cites this paper